Research Study

Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With Cellectra-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18
Principal Investigator 
Dianne M. Miller

Overview

Body Locations and Systems 
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01304524
Status 
Closed to Recruitment
Study Start/End 
Oct 3, 2011 to Jul 30, 2018
Locations 
Diamond Health Care Centre
Name/Title 
Susan Keast, Research Coordinator
Phone 
604-875-4111 ext.67968
Email Address 
susan.keast@vch.ca
Purpose of Study 

This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18 associated Cervical intraepithelial neoplasia grade 2/3 or 3.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.